Through flavination and stabilization of ETF, riboflavin therapy has been found to be effective in treating MADD, an autosomal recessively inherited disorder mainly caused by a defect in the ETF gene (Gregersen et al, 1986; Wen et al, 2010; Cornelius et al, 2012; Manole et al, 2017). This evidence concerns the gene TEAD2 and multiple acyl-CoA dehydrogenase deficiency.